CAR T cells
World’s Largest Cell and Gene Therapy Plant Opens
World’s Largest Cell and Gene Therapy Plant Opens
Catherine Offord | Apr 11, 2018
Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Catherine Offord | Dec 17, 2017
More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 
Antiviral Immunotherapy Comes of Age
Antiviral Immunotherapy Comes of Age
Lucas Laursen | Dec 4, 2017
T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 
Researchers Build a Cancer Immunotherapy Without Immune Cells
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena | Nov 13, 2017
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 
FDA Approves Second CAR T-Cell Therapy
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 
First CAR T-Cell Therapy Approved in U.S.
First CAR T-Cell Therapy Approved in U.S.
Shawna Williams | Aug 30, 2017
The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Ever-Expanding T-Cell World: A Primer
The Ever-Expanding T-Cell World: A Primer
Ashley P. Taylor | Aug 7, 2017
Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer. The Scientist attempts to catalog them all.